Chemo campaign gathers support

Stobhill Hospital
Stobhill Hospital

Demand is rising for 
chemotherapy services to 
be made available for cancer patients at the ‘new’ Stobhill Hospital.

Patients and their families posted on the Herald’s Facebook page after leading campaigner Tom Herbert met with NHS Greater Glasgow and Clyde chief executive Robert Calderwood last week.

They were unanimous in supporting the service being made available at Stobhill to make life less stressful for themselves or their families.

Campaigners want the Stobhill ACAD to provide a similar service to that delivered at the ‘new’ Victoria Infirmary on the southside of Glasgow.

Local woman Linzi MacMillan-McColl spoke of the plight of her mum.

She said: “Stobhill needs it. My mum is a breast and lymph node cancer 
survivor for two years.

“The necessary trips to and from the Beatson took a lot out of her.”

Victoria Crainey added: “I had to take my mum to the Beatson just recently for five days a week for six weeks.

“It would be so much 
better if they could do it at Stobhill for people in theses areas .

Susan Hannah was stunned the service was not provided in a hospital so close to her home.

She said: “It’s shocking that we have Stobhill so near and it’s not used for these 

Yvonne Wilson, Frances Smith and Paul O’Connor both said Stobhill sorely needed the service.

Health Board chief executive Robert Calderwood said last week he wanted to continue to review the service in “an open and transparent way.”

Tom Herbert told the Herald the meeting with the health boss was “positive” and he had come away “reasonabley confident” progress had been made.

As part of a clinical services review, the health board is looking at how healthcaare will be delivered in 2015 and beyond.

A spokesperson for the board said last week: “The work is being undertaken by eight clinical working groups working with patients and other stakeholders.

“One of the groups is looking at cancer services and in particular how we can deliver oral chemotherapy as close to the patient as possible, and clinically safe. This work is ongoing.”